Related Experiment Video

Updated: Jul 25, 2025

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

16.6K

Management of Neonatal Isolated and Combined Growth Hormone Deficiency: Current Status

Stefano Stagi1,2, Maria Tufano3, Nicolò Chiti1

  • 1Department of Health Sciences, University of Florence, 50139 Florence, Italy.

International Journal of Molecular Sciences
|June 28, 2023
PubMed

Insights

Congenital growth hormone deficiency (GHD) is a rare pituitary disorder. Early diagnosis via lab tests and prompt growth hormone replacement therapy improve patient outcomes.

Area of Science:

  • Pediatric Endocrinology
  • Genetics
  • Metabolic Disorders

Background:

  • Congenital growth hormone deficiency (GHD) stems from pituitary gland developmental issues.
  • GHD can occur alone or with other pituitary hormone deficiencies.
  • Genetic factors can underlie some cases of congenital GHD.

Purpose of the Study:

  • To summarize the key aspects of congenital growth hormone deficiency.
  • To highlight diagnostic criteria and treatment approaches for GHD.
  • To emphasize the benefits of early intervention in GHD management.

Main Methods:

  • Review of clinical signs and symptoms of GHD.
  • Emphasis on laboratory diagnostic analyses over imaging.
  • Discussion of hormone replacement therapy protocols.

Main Results:

  • Clinical manifestations include hypoglycemia, neonatal cholestasis, and micropenis.
  • Laboratory testing is the preferred diagnostic method for GHD.
  • Early growth hormone replacement therapy yields significant benefits.

Conclusions:

  • Prompt diagnosis and treatment of congenital GHD are crucial.
  • Early growth hormone therapy improves growth, metabolism, and neurodevelopment.
  • Management focuses on laboratory confirmation and timely hormone replacement.

Keywords:
cognition disorders/physiopathologycongenital hypopituitarismgrowth hormonegrowth hormone deficiencyhormone replacement therapyhypoglycaemianewborn

More Related Videos

Isolation of Neonatal Extrahepatic Cholangiocytes07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

10.3K
Delivery of In Vivo Acute Intermittent Hypoxia in Neonatal Rodents to Prime Subventricular Zone-derived Neural Progenitor Cell Cultures05:45

Delivery of In Vivo Acute Intermittent Hypoxia in Neonatal Rodents to Prime Subventricular Zone-derived Neural Progenitor Cell Cultures

Published on: November 2, 2015

7.3K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
20.6K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
205
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
199
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.4K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
214